SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
SEC Accession No. 0001185185-19-001621
Filing Date
2019-11-18
Accepted
2019-11-18 11:55:36
Documents
5

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D/A dangdai20191118_sc13da.htm SC 13D/A 75707
2 EXHIBIT 1 ex_165264.htm EX-1 197115
3 EXHIBIT 2-A ex_165265.htm EX-2.A 36987
4 EXHIBIT 2-B ex_165266.htm EX-2.B 37052
5 EXHIBIT 3 ex_165267.htm EX-3 36467
  Complete submission text file 0001185185-19-001621.txt   385033
Mailing Address 1345 AVENUE OF THE AMERICAS 11TH FLOOR NEW YORK NY 10105
Business Address 1345 AVENUE OF THE AMERICAS 11TH FLOOR NEW YORK NY 10105 (347) 905 5663
Cellular Biomedicine Group, Inc. (Subject) CIK: 0001378624 (see all company filings)

IRS No.: 861032927 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-82437 | Film No.: 191226619
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 369 LUMO ROAD HONGSHAN DISTRICT WUHAN, HUBEI F4 430070
Business Address 369 LUMO ROAD HONGSHAN DISTRICT WUHAN, HUBEI F4 430070 86-027-87596552
Dangdal International Group Co. Ltd (Filed by) CIK: 0001678024 (see all company filings)

IRS No.: 000000000 | State of Incorp.: K3 | Fiscal Year End: 1231
Type: SC 13D/A